ArticleBMC cardiovascular disorders2025
Association of estimated plasma volume status with 30-day mortality risk in patients with cardiogenic shock: an analysis based on MIMIC-IV database.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic value of glycaemic variability for mortality in cardiogenic shock patients: a retrospective cohort study.Cardiovascular diabetology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough estimated plasma volume status (ePVS) has been proven a simple and effective predictor of mortality in many diseases. However, the prognostic value of ePVS in critically ill patients with cardiogenic shock (CS) remains unknown. This study aims to assess the association between ePVS and 30-day mortality risk in CS patients.
methodThis retrospective cohort study extracted data on patients diagnosed with CS from the Medical Information Mart for Intensive Care-IV (MIMIC-IV) database. The endpoint of the study was 30-day mortality from the intensive care unit admission. The ePVS were assessed by Kaplan Hakim (KH-ePVS), and Duarte-ePVS. The optimal cut-off values were determined using the maximum selection method to classify the ePVS into two groups, and their baseline characteristics were compared. Cox proportional hazards model and Kaplan-Meier survival curves were used to assess the association between ePVS levels and 30-day mortality.
resultsA total of 1,691 participants were recruited in this study, with 596 participants (35.25%) dying within 30 days. Patients with higher Duarte-ePVS levels had a higher risk of 30-day mortality [HR (hazard ratios): 1.36, 95% confidence interval (CI): 1.12-1.65] compared with CS patients with lower Duarte-ePVS levels. However, no association was observed between KH-ePVS and 30-day mortality risk in critically ill CS patients (HR: 1.19, 95%CI: 0.96-1.48). Similar results of the association between ePVS and 30-day mortality were found in participants aged ≥ 65 years, male, and those with heart failure (all P < 0.05). Kaplan-Meier curves showed that Duarte-ePVS ≥ 5.11 or KH-ePVS ≥ -10.04 were associated with an increased risk of death (P < 0.001).
conclusionHigher levels of ePVS are associated with an increased risk of short-term mortality in critically ill CS patients. EPVS could potentially be used as a biomarker to enhance the management of patients with CS, although additional research is necessary to assess its predictive utility. Our study offers initial insights that may support risk assessment and prognosis evaluation in CS patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.